Alleviation of experimental cyclosporin A nephrotoxicity by low dose aspirin in the rat

K. E. Adams, P. A.J. Brown, S. D. Heys, P. H. Whiting*

*Corresponding author for this work

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Groups of male Sprague-Dawley rats recieved either cyclosporin A (CsA; 25 mg/kg by gavage), low dose aspirin (ASP; 20 mg/kg by gavage), a combination of both, or the appropriate drug vehicles daily for 14 days. Renal structure and function were assessed on day 0 (pretreatment) and on days 7 and 14. Compared to pretreatment results. CsA nephrotoxicity was characterized by increased plasma urea and creatinine concentrations and by moderate to severe microcalcification (MC) at the corticomedullary junction by day 14. The development of nephrotoxicity was also associated with a 5-fold increase in urine thromboxane B2 (TxB2) excretion by day 10, while that of 6-ketoprostaglandin F remained relatively constant. Although both ASP and saline (ASP vehicle) -cotreated animals demonstrated significantly lower plasma urea and creatinine concentrations compared to treatment with CsA alone, the severity of MC observed on day 14, was reduced only in the ASP cotreatment group. Trough whole blood CsA concentrations were similar at around 2400 ng/mL in all experimental groups. In addition, although a 2-fold increase in urine TxB2 excretion was observed on days 7 and 10 following treatment with CsA/ASP, levels were significantly reduced compared to treatment with either CsA alone or CsA/saline (both P<0.05).

Original languageEnglish
Pages (from-to)2104-2108
Number of pages5
JournalBIOCHEMICAL PHARMACOLOGY
Volume46
Issue number11
DOIs
Publication statusPublished - 3 Dec 1993

Fingerprint

Calcinosis
Thromboxane B2
Cyclosporine
Aspirin
Urea
Rats
Creatinine
Urine
Plasmas
Sprague Dawley Rats
Animals
Blood
Kidney
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Alleviation of experimental cyclosporin A nephrotoxicity by low dose aspirin in the rat. / Adams, K. E.; Brown, P. A.J.; Heys, S. D.; Whiting, P. H.

In: BIOCHEMICAL PHARMACOLOGY, Vol. 46, No. 11, 03.12.1993, p. 2104-2108.

Research output: Contribution to journalArticle

Adams, K. E. ; Brown, P. A.J. ; Heys, S. D. ; Whiting, P. H. / Alleviation of experimental cyclosporin A nephrotoxicity by low dose aspirin in the rat. In: BIOCHEMICAL PHARMACOLOGY. 1993 ; Vol. 46, No. 11. pp. 2104-2108.
@article{959b3636bbca4b0b97dde7284c7442ca,
title = "Alleviation of experimental cyclosporin A nephrotoxicity by low dose aspirin in the rat",
abstract = "Groups of male Sprague-Dawley rats recieved either cyclosporin A (CsA; 25 mg/kg by gavage), low dose aspirin (ASP; 20 mg/kg by gavage), a combination of both, or the appropriate drug vehicles daily for 14 days. Renal structure and function were assessed on day 0 (pretreatment) and on days 7 and 14. Compared to pretreatment results. CsA nephrotoxicity was characterized by increased plasma urea and creatinine concentrations and by moderate to severe microcalcification (MC) at the corticomedullary junction by day 14. The development of nephrotoxicity was also associated with a 5-fold increase in urine thromboxane B2 (TxB2) excretion by day 10, while that of 6-ketoprostaglandin F1α remained relatively constant. Although both ASP and saline (ASP vehicle) -cotreated animals demonstrated significantly lower plasma urea and creatinine concentrations compared to treatment with CsA alone, the severity of MC observed on day 14, was reduced only in the ASP cotreatment group. Trough whole blood CsA concentrations were similar at around 2400 ng/mL in all experimental groups. In addition, although a 2-fold increase in urine TxB2 excretion was observed on days 7 and 10 following treatment with CsA/ASP, levels were significantly reduced compared to treatment with either CsA alone or CsA/saline (both P<0.05).",
author = "Adams, {K. E.} and Brown, {P. A.J.} and Heys, {S. D.} and Whiting, {P. H.}",
year = "1993",
month = "12",
day = "3",
doi = "10.1016/0006-2952(93)90655-G",
language = "English",
volume = "46",
pages = "2104--2108",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Alleviation of experimental cyclosporin A nephrotoxicity by low dose aspirin in the rat

AU - Adams, K. E.

AU - Brown, P. A.J.

AU - Heys, S. D.

AU - Whiting, P. H.

PY - 1993/12/3

Y1 - 1993/12/3

N2 - Groups of male Sprague-Dawley rats recieved either cyclosporin A (CsA; 25 mg/kg by gavage), low dose aspirin (ASP; 20 mg/kg by gavage), a combination of both, or the appropriate drug vehicles daily for 14 days. Renal structure and function were assessed on day 0 (pretreatment) and on days 7 and 14. Compared to pretreatment results. CsA nephrotoxicity was characterized by increased plasma urea and creatinine concentrations and by moderate to severe microcalcification (MC) at the corticomedullary junction by day 14. The development of nephrotoxicity was also associated with a 5-fold increase in urine thromboxane B2 (TxB2) excretion by day 10, while that of 6-ketoprostaglandin F1α remained relatively constant. Although both ASP and saline (ASP vehicle) -cotreated animals demonstrated significantly lower plasma urea and creatinine concentrations compared to treatment with CsA alone, the severity of MC observed on day 14, was reduced only in the ASP cotreatment group. Trough whole blood CsA concentrations were similar at around 2400 ng/mL in all experimental groups. In addition, although a 2-fold increase in urine TxB2 excretion was observed on days 7 and 10 following treatment with CsA/ASP, levels were significantly reduced compared to treatment with either CsA alone or CsA/saline (both P<0.05).

AB - Groups of male Sprague-Dawley rats recieved either cyclosporin A (CsA; 25 mg/kg by gavage), low dose aspirin (ASP; 20 mg/kg by gavage), a combination of both, or the appropriate drug vehicles daily for 14 days. Renal structure and function were assessed on day 0 (pretreatment) and on days 7 and 14. Compared to pretreatment results. CsA nephrotoxicity was characterized by increased plasma urea and creatinine concentrations and by moderate to severe microcalcification (MC) at the corticomedullary junction by day 14. The development of nephrotoxicity was also associated with a 5-fold increase in urine thromboxane B2 (TxB2) excretion by day 10, while that of 6-ketoprostaglandin F1α remained relatively constant. Although both ASP and saline (ASP vehicle) -cotreated animals demonstrated significantly lower plasma urea and creatinine concentrations compared to treatment with CsA alone, the severity of MC observed on day 14, was reduced only in the ASP cotreatment group. Trough whole blood CsA concentrations were similar at around 2400 ng/mL in all experimental groups. In addition, although a 2-fold increase in urine TxB2 excretion was observed on days 7 and 10 following treatment with CsA/ASP, levels were significantly reduced compared to treatment with either CsA alone or CsA/saline (both P<0.05).

UR - http://www.scopus.com/inward/record.url?scp=0027442714&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(93)90655-G

DO - 10.1016/0006-2952(93)90655-G

M3 - Article

VL - 46

SP - 2104

EP - 2108

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -